Announcements Trials
Browse Landscape

Phase

Phase 2 73Phase 3 21Phase 2/3 10Phase 1 6Phase 1/2 5Phase 4 4Phase NA 3

Status

Unknown 14Completed 14Not yet recruiting 4Active not recruiting 3Recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 2NET 1Gastrointestinal 1Endocrine 1

Conditions

Small Cell Lung Carcinoma 2Neuroendocrine Tumors 1Esophageal Squamous Cell Carcinoma 1

Interventions

Carboplatin 6anlotinib 5lenvatinib 4Oxaliplatin 4Immune Checkpoint Inhibitors 4Cisplatin 4tislelizumab 3sintilimab 3Fluorouracil 3Capecitabine 3venetoclax 2Rosuvastatin Calcium 2Prednisone 2Megestrol Acetate 2Leucovorin 2Drug Therapy 2Dexmedetomidine 2Dexamethasone 2Cyclophosphamide 2Bevacizumab 2Aspirin 2zanubrutinib 1xiaojin wan 1trastuzumab deruxtecan 1trametinib 1tocilizumab 1testosterone 17 beta-cypionate 1tenofovir alafenamide 1telitacicept 1taxane 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 4 × Not yet recruiting × Cisplatin × Clear all
NCT06951841 2025-04-30

Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

China Medical University, China

Phase 4 Not yet recruiting
31 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT06931145 2025-04-23

Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer

Peking Union Medical College Hospital

Phase 4 Not yet recruiting
50 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT06485739 2024-07-03

Irinotecan Liposomes for the Treatment of Neuroendocrine Carcinoma

First Affiliated Hospital Xi'an Jiaotong University

Phase 4 Not yet recruiting
20 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT06388135 2024-04-29

Serplulimab Combined With Nab-paclitaxel and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma

Xijing Hospital

Phase 4 Not yet recruiting
80 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡